Ospemifene

Ospemifene is an oral medication that offers an alternative approach to treating vaginal dryness and related symptoms in postmenopausal women. Unlike vaginal estrogen creams and suppositories that work locally, ospemifene is a systemic medication taken as a tablet. It works through a completely different mechanism than direct hormone replacement, making it valuable for women who can't or won't use vaginal estrogen but need treatment for vaginal symptoms.

What Is a SERM?

Ospemifene is a selective estrogen receptor modulator, abbreviated SERM. SERMs are medications that interact with estrogen receptors throughout the body, but they act as estrogen agonists in some tissues and antagonists in others. This selectivity means they can mimic estrogen's beneficial effects in some organs while blocking its effects in others.

The most well-known SERM is tamoxifen, a breast cancer treatment that blocks estrogen in breast tissue but acts as estrogen in bone and uterine tissue. Raloxifene, used for osteoporosis prevention, is another SERM that acts as estrogen in bone while antagonizing it in breast tissue.

Ospemifene, approved by the FDA in 2013, is the first SERM specifically approved for vaginal atrophy in postmenopausal women. It was developed specifically to act as an estrogen in vaginal and urethral tissues while not exerting estrogenic effects in breast or endometrial tissue.

How Ospemifene Works

In vaginal tissue, ospemifene acts as an estrogen agonist, stimulating estrogen receptors and promoting the growth and health of vaginal epithelial cells. This increases vaginal blood flow, improves lubrication capacity, and thickens the vaginal epithelium, which becomes thin and fragile in estrogen deficiency.

Ospemifene also affects the vaginal microbiota and pH. Estrogen-deficient vaginal tissue has abnormal bacterial balance and elevated pH. Ospemifene restores more normal conditions.

The oral route means ospemifene reaches vaginal tissue through systemic absorption and local accumulation, not through direct local application. This is fundamentally different from vaginal estrogen, which delivers hormone directly to the target tissue with minimal systemic absorption.

Clinical Evidence

Ospemifene was studied in multiple randomized, placebo-controlled trials in postmenopausal women with moderate to severe vaginal symptoms. Women received either 60 milligrams daily of ospemifene or placebo for 12 weeks.

Results showed that ospemifene reduced vaginal dryness, improved vaginal health using objective measures like vaginal maturation index, reduced dyspareunia (pain with intercourse), and improved overall sexual satisfaction. Improvements were consistent across studies and across age groups and races of menopausal women.

Compared to placebo, ospemifene showed meaningful benefit. Compared to vaginal estrogen in studies where both were examined, efficacy appeared comparable, though head-to-head comparison studies are limited.

The benefit was apparent within 2 to 3 weeks and continued improving through the 12-week study period. Whether benefits continue with longer use and whether they persist after stopping ospemifene is less well characterized.

Dosing

Ospemifene is taken as a 60-milligram tablet once daily, taken with food. This is the standard dose. There's no dose escalation or adjustment based on response; the dose is fixed.

Taking it with food improves absorption. The medication is absorbed through the intestinal tract and metabolized by the liver, similar to many oral medications.

Side Effects and Tolerability

Common side effects in clinical trials included hot flashes, which paradoxically occurred in women already menopausal. Some women taking ospemifene experienced increased hot flashing despite being years past their final menstrual period. This occurs in roughly 5 to 10 percent of women and can be bothersome enough to warrant discontinuing the medication.

Vaginal discharge increased in some women, sometimes to an extent that required wearing pads. This reflects improved vaginal health and lubrication but can be annoying.

Other side effects included muscle aches, rashes, and headache, though these occurred at rates similar to placebo and weren't specific medication effects.

Serious adverse events were rare and occurred at similar rates between ospemifene and placebo, suggesting the medication wasn't associated with serious safety signals in the studied populations.

Safety Considerations

Ospemifene carries warnings similar to hormone therapy regarding blood clots. Because it stimulates estrogen receptors, it increases thrombotic risk slightly. This risk is higher in women who smoke, have personal or family history of blood clots, have prolonged immobility, or have other clotting risk factors.

The increased thrombotic risk, while modest, means ospemifene isn't appropriate for women with a history of deep venous thrombosis or pulmonary embolism. Women with leg immobility or prolonged bed rest should discuss use carefully with their doctors.

Endometrial hyperplasia, overgrowth of the endometrial lining, has been reported in women taking ospemifene. This is paradoxical because ospemifene acts as an estrogen antagonist in the endometrium in laboratory studies, but clinical cases suggest it sometimes causes endometrial effects. The incidence is low, but any vaginal bleeding warrants gynecological evaluation to rule out endometrial problems.

Breast cancer risk from ospemifene is incompletely understood. No increased breast cancer incidence was seen in clinical trials, but trials weren't specifically powered to detect cancer risk, and follow-up times were limited. Theoretically, because ospemifene is a SERM that acts as an estrogen antagonist in breast tissue, it might reduce breast cancer risk similarly to raloxifene. However, individual variation exists, and some SERMs increase risk in specific populations.

Current evidence doesn't show ospemifene increases breast cancer risk, but caution is recommended in women with a personal history of breast cancer or strong family history.

Comparison to Vaginal Estrogen

Vaginal estrogen, available as creams, tablets, or rings, delivers estrogen directly to vaginal tissue with minimal systemic absorption. This provides very effective local treatment with less systemic hormone exposure than ospemifene.

For women who can comfortably use vaginal estrogen, it's typically first-line treatment because it's more directly targeted, provides high local hormone concentration, and has minimal systemic effects.

However, some women can't or won't use vaginal estrogen. Those who find applicators difficult to use, who have dexterity problems making applicator use challenging, or who simply prefer not to use a product inserted vaginally might prefer oral ospemifene.

Women who have concerns about systemic hormone absorption from vaginal estrogen might actually prefer ospemifene, despite ospemifene being systemic. This seems paradoxical but reflects misunderstanding about vaginal estrogen's systemic absorption. Vaginal estrogen actually has minimal systemic absorption; ospemifene has more.

Ospemifene is less effective at achieving very high local hormone concentrations than vaginal estrogen, which might mean slightly less impressive symptom relief for some women.

Ospemifene vs Hormone Replacement

For women who are already on systemic hormone replacement therapy, ospemifene offers less than continuing or increasing systemic hormone therapy, because the estrogen they're already taking should adequately treat vaginal symptoms.

For women who aren't on systemic hormone therapy but who have vaginal symptoms, ospemifene is one option. However, it doesn't address hot flashes or other systemic menopausal symptoms the way systemic HRT does.

For women specifically wanting treatment for vaginal symptoms only, without systemic hormone effects, ospemifene provides those effects more systemically than local vaginal estrogen but less systemically than hormone replacement.

Who Might Choose Ospemifene

Women who can't use vaginal estrogen due to practical difficulties or preferences represent the main potential beneficiaries. Women who have contraindications to vaginal estrogen (though truly absolute contraindications are rare) might use ospemifene.

Women who have tried vaginal estrogen and had inadequate response might add ospemifene, though this hasn't been specifically studied.

Women who strongly prefer oral medication to topical or inserted treatments represent another group who might choose ospemifene despite potentially having access to vaginal therapy.

Cost and Access

Ospemifene is a branded medication with limited generic availability, and cost can be significant. Insurance coverage varies. Some plans cover it readily; others require prior authorization or don't cover it. The cost may be prohibitive for uninsured women.

Vaginal estrogen is available in multiple generic formulations and is typically much less expensive, making it more accessible for many women.

Practical Considerations

Ospemifene requires daily adherence over time. It's not a one-time or as-needed treatment. This differs from vaginal estrogen, which is typically used several times weekly once symptoms improve.

The increased hot flashing that occurs in some women taking ospemifene can be particularly frustrating for women who've already moved past the hot flashing phase of menopause. Finding this new symptom arising from vaginal treatment is unexpected and bothersome.

The improvement in vaginal symptoms may take weeks to become apparent, so patience is needed before evaluating whether the medication is working.

The Bigger Picture

Ospemifene offers a valuable option for vaginal atrophy treatment, particularly for women who prefer oral medication or who can't use vaginal estrogen. It's not first-line for most women, as vaginal estrogen is more direct and targeted, but for the specific population it serves, it provides a meaningful treatment option.

Understanding ospemifene's place among vaginal symptom treatments helps you and your healthcare provider choose the best approach for your particular situation. Whether vaginal estrogen, ospemifene, systemic hormone therapy, or non-hormonal approaches work best depends on your specific symptoms, preferences, medical history, and access to treatments.